Based on a futility analysis by the independent Data Safety Monitoring Board, the ongoing Phase 2/3 clinical trial evaluating Biohaven Pharmaceuticals’ (NYSE:BHVN) troriluzole in Alzheimer’s disease patients will continue as planned.
The primary endpoints are the change from baseline in two AD scales, ADAS-Cog 11 and CDR-Sum of boxes, at week 48 compared to placebo. The estimated completion date is December 2020.
On another note, the USPTO has issued a new composition of matter patent covering troriluzole with an expiration date of February 26, 2036.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.